Biotech Values

[biomaven0]

>>Teva contends that any company that files an application for any glatiramoid, via an ANDA or 505(b)(2) application, should conduct pre-clinical testing as well as full-scale, placebo-controlled clinical trials with measured clinical endpoints in MS patients to establish safety, efficacy and immunogenicity in this patient population.<<

So funny to see them on the other side of the fence. Their patent attorneys must be freaking out and having to copy their normal opponents' boiler plate instead of their own.